NET PROFIT (x1000 NOK)
EMPLOYEES
Hamlet BioPharma AB
Closing information (x1000 NOK)
| Closing information | 2024/06 (consolidated) | 2023/06 (consolidated) | 2022/06 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
0
|
0
|
74 |
| Earnings before taxes |
-41,953
|
-20,246
|
-16,673 |
| EBITDA |
-33,037
|
-19,848
|
-16,591 |
| Total assets |
68,789
|
28,218
|
40,461 |
| Current assets |
27,389
|
18,832
|
40,461 |
| Current liabilities |
4,121
|
2,525
|
3,605 |
| Equity capital |
64,668
|
20,741
|
36,856 |
| - share capital |
1,683
|
1,109
|
1,071 |
| Employees (average) |
7
|
4
|
4 |
Financial ratios
| Fiscal year | 2024/06 (consolidated) | 2023/06 (consolidated) | 2022/06 |
| Solvency |
94.0%
|
73.5%
|
91.1% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-61.0%
|
-71.7%
|
-41.0% |
| Current ratio |
664.6%
|
745.8%
|
1122.4% |
| Return on equity (ROE) |
-64.9%
|
-97.6%
|
-45.2% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
3
|
0
|
0 |
| Chg. No. of employees % | 75% | 0% |
Total value of public sale
| Fiscal year | 2024/06 (consolidated) | 2023/06 (consolidated) | 2022/06 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.